At the inquiry
Qualified leads
Claimants screened against your firm’s Oxbryta criteria, delivered with their responses to your intake team or CRM.
For teams that handle follow-up and conversion.
Discuss qualified leadsPfizer withdrew the sickle cell disease drug Oxbryta (voxelotor) from all markets in September 2024, citing an imbalance in vaso-occlusive crises and fatal events. Litigation is early; we screen claimants against your firm’s criteria.
Discuss a campaignSummary of public information for law firms. Not legal advice.
Delivery models
The right model depends on your intake capacity and acquisition economics.
At the inquiry
Claimants screened against your firm’s Oxbryta criteria, delivered with their responses to your intake team or CRM.
For teams that handle follow-up and conversion.
Discuss qualified leadsAt the conversation
Screened claimants connected directly with your intake team during agreed hours and within your delivery caps.
For teams ready to take a live call.
How live transfers workAt the retainer
For select programs, acquisition structured around qualified, completed e-signed retainers.
For firms seeking a retained-client model.
About retainer programsThe litigation · October 2026
Litigation moves quickly. We confirm current status, and whether a program fits your firm’s strategy, before launch.
SourcesOxbryta received FDA accelerated approval to treat sickle cell disease.
Pfizer withdrew all lots worldwide, stating that the overall benefit no longer outweighed the risk, with data suggesting an imbalance in vaso-occlusive crises and fatal events.
Individual and class claims have been filed. As of our October 2026 review, no MDL had been created.
Screening
These are the areas Oxbryta screening typically covers. The exact questions and thresholds come from your firm.
Talk through your criteriaWhether the claimant took Oxbryta, when and for how long.
Vaso-occlusive crises, hospitalizations or other outcomes your firm accepts, including wrongful death.
Prescription and medical records available to document use and events.
Whether the claimant or family already has an attorney.
Questions
Answers specific to your program are part of the first conversation.
Not as of our October 2026 review. Litigation is at an early stage, and we confirm current status with your firm before launch.
People with sickle cell disease who took Oxbryta, and families in wrongful death cases, depending on your firm’s criteria.
Where a program requires it, leads can be delivered with a TrustedForm or Jornaya certificate. Call recordings for transfers depend on program support and applicable consent requirements.
Sources
Summary of public information as of October 2026, for law firms evaluating case acquisition. It is not legal advice, and litigation status changes.
Other torts
Start a conversation
Send the practice area, criteria and volume you have in mind. We’ll talk through the right delivery model and a sensible starting point.
Book a 30-minute intro call